preval
viral
diseas
increas
due
avail
modern
diagnost
test
allow
rapid
detect
virus
viral
diseas
may
addit
associ
signific
morbid
mortal
case
emerg
viral
diseas
middl
east
respiratori
syndrom
coronaviru
avian
influenza
patient
sever
viral
infect
often
hospit
intens
care
unit
icu
hand
recent
studi
underlin
frequenc
viru
detect
icu
patient
major
viral
infect
requir
icu
care
involv
respiratori
tract
central
nervou
system
howev
organ
system
gastrointestin
tract
may
sever
affect
virus
requir
support
close
monitor
report
incid
viral
infect
report
icu
vari
wide
across
studi
geograph
region
chang
recent
year
base
epidemiolog
emerg
viral
infect
human
metapneumoviru
adenoviru
infect
improv
molecular
detect
method
also
significantli
chang
epidemiolog
viral
infect
icu
last
year
multiinstitut
databas
timeseri
model
may
use
tool
character
forecast
burden
sever
viral
infect
local
institut
level
clinic
sign
symptom
rare
suffici
make
specif
diagnosi
viral
infect
often
combin
appropri
clinic
syndrom
togeth
epidemiolog
clue
importantli
specif
laboratori
test
use
reach
diagnosi
viral
infect
caus
sever
morbid
mortal
certain
host
immunocompromis
patient
tabl
herein
review
literatur
role
virus
icu
adult
exclud
human
immunodefici
viru
hiv
focu
treatment
infect
recent
year
virus
identifi
increasingli
frequent
caus
communityacquir
pneumonia
cap
avail
new
diagnost
tool
polymeras
chain
reaction
pcr
hand
emerg
pandem
influenza
viru
well
emerg
virus
pandem
potenti
avian
influenza
virus
new
coronavirus
emphas
role
virus
sever
commun
acquir
pneumonia
place
virus
endem
viral
nosocomi
pneumonia
hospitalacquir
healthcareassoci
pneumonia
hcap
ventilatorassoci
pneumonia
vap
describ
pathogen
role
virus
recov
lower
respiratori
tract
patient
pneumonia
remain
controversi
sever
viral
infect
influenza
sever
acut
respiratori
syndrom
sar
may
caus
respiratori
failur
may
rapidli
progress
acut
respiratori
distress
syndrom
ard
multiorgan
failur
except
pneumonia
acut
respiratori
failur
occur
patient
chronic
obstruct
pulmonari
diseas
copd
lead
hospit
need
mechan
ventil
addit
virus
caus
ard
neurogen
respiratori
failur
exampl
develop
syndrom
although
sever
communityacquir
pneumonia
usual
caus
bacteria
virus
account
approxim
case
larg
seri
common
caus
viral
pneumonia
adult
influenza
viru
type
b
immunocompromis
patient
like
viral
pneumonia
caus
respiratori
syncyti
viru
rsv
cytomegaloviru
cmv
herp
simplex
viru
hsv
varicellazost
viru
vzv
adenoviru
rare
measl
recent
molecular
diagnost
method
significantli
chang
epidemiolog
viral
pneumonia
icu
last
year
increas
detect
virus
human
metapneumoviru
adenoviru
infect
radiograph
find
variabl
viru
specif
atyp
pneumonia
present
often
seen
otherwis
healthi
individu
hand
sever
lobar
bilater
pneumonia
seen
immunocompromis
host
report
respiratori
virus
caus
sever
pneumonia
acut
respiratori
distress
syndrom
ard
requir
mechan
ventil
frequenc
complic
known
viral
pneumonia
may
nosocomi
acquir
especi
peak
respiratori
period
immunocompromis
patient
recent
retrospect
studi
hcap
patient
least
one
respiratori
viru
recov
either
lower
respiratori
tract
nasopharyng
swab
frequent
rhinoviru
parainfluenza
viru
human
metapneumoviru
influenza
patient
viral
hcap
bacteri
vap
mortal
rate
although
data
viral
nosocomi
pneumonia
scarc
role
respiratori
virus
caus
nosocomi
pneumonia
probabl
limit
two
studi
icu
patient
mechan
ventil
patient
vap
respiratori
sampl
posit
respiratori
virus
mani
case
mechan
ventil
durat
viru
detect
may
indic
carriag
icu
admiss
latent
virus
herpesvirida
includ
herp
simplex
viru
hsv
cytomegaloviru
cmv
known
caus
pneumonia
system
diseas
immunocompromis
patient
often
reactiv
nonimmunocompromis
icu
patient
icu
patient
known
experi
immunoparalysi
sinc
initi
proinflammatori
follow
antiinflammatori
respons
immunolog
state
respons
nosocomi
infect
latent
viru
reactiv
patient
viral
detect
reflect
viral
reactiv
without
lung
parenchym
involv
howev
viral
lung
diseas
may
develop
usual
patient
prolong
mechan
ventil
mimiviru
emerg
viru
also
describ
possibl
caus
nosocomi
vap
although
patient
high
hsv
cmv
viremia
often
wors
prognosi
exact
signific
detect
hsv
cmv
mimiviru
lower
respiratori
tract
ventil
nonimmunocompromis
icu
patient
unclear
clinic
research
work
need
elucid
role
virus
pathogenesi
nosocomi
viral
pneumonia
influenza
viru
food
drug
administr
fda
approv
therapeut
agent
avail
adult
effect
measur
influenza
remain
vaccin
particularli
elderli
highrisk
individu
antivir
treatment
influenza
includ
channel
inhibitor
neuraminidas
inhibitor
although
treatment
neuraminidas
inhibitor
oseltamivir
zanamivir
recommend
patient
suspect
confirm
influenza
requir
hospit
use
nonsever
influenza
could
harm
benefici
possibl
select
resist
mutant
thu
would
appropri
use
patient
sever
diseas
present
exampl
sever
pneumonia
requir
mechan
ventil
patient
high
risk
influenza
associ
complic
eg
immunocompromis
individu
altern
use
suspect
case
area
endem
strain
high
mortal
eg
avian
influenza
strain
higher
dose
regimen
mg
twice
daili
may
safe
well
toler
use
treat
serious
ill
patient
may
benefit
treatment
influenza
b
influenza
strain
reduc
suscept
well
infect
site
limit
drug
penetr
eg
central
nervou
system
case
howev
overal
support
evid
lack
antivir
resist
may
emerg
even
higher
dose
oseltamivir
two
new
neuraminidas
inhibitor
recent
describ
peramivir
laninamivir
octano
peramivir
given
singl
intraven
dose
author
short
period
us
food
drug
administr
fda
emerg
intraven
use
hospit
patient
pandem
influenza
viru
laninamivir
given
singl
inhal
dose
treatment
season
influenza
adult
may
also
treat
oseltamivirresist
viru
addit
new
therapeut
treatment
influenza
viru
infect
develop
regard
drug
favipiravir
shown
inhibit
varieti
influenza
virus
includ
highli
pathogen
avian
influenza
virus
final
numer
antivir
entri
inhibitor
nucleosid
analogu
cidofovir
viral
enzym
inhibitor
terminas
helicas
enzym
inhibitor
translat
inhibitor
may
util
offlabel
indic
treatment
viral
infect
except
hiv
hepat
c
hepat
b
combin
drug
therapi
establish
virus
hsv
influenza
tripl
dual
drug
combin
may
synergist
antivir
action
efficaci
oseltamivirzanamivir
combin
season
influenza
establish
random
control
clinic
studi
howev
clinic
antagon
oseltamivir
zanamivir
suggest
anoth
studi
lowdos
system
corticosteroid
may
use
septic
shock
relat
sever
influenza
sinc
evid
rct
suggest
corticosteroid
may
associ
delay
clearanc
virus
invas
fungal
infect
case
control
studi
rct
suggest
plasma
hyperimmun
globulin
demonstr
favor
respons
patient
sever
avian
influenza
infect
compar
control
evalu
novel
treatment
rct
need
sever
virus
may
caus
infecti
postinfecti
complic
nervou
system
tabl
despit
advanc
molecular
techniqu
specif
caus
found
less
half
case
acyclovir
significantli
improv
prognosi
hsv
enceph
although
without
treatment
mortal
decreas
mani
survivor
persist
neurolog
deficit
prognosi
viral
encephalitid
gener
compar
hsv
enceph
neurolog
system
complic
may
exacerb
brain
damag
identifi
treat
earli
support
therapi
optim
neurolog
recoveri
tabl
evid
rct
lack
thu
corticosteroid
use
routin
may
use
select
case
signific
edema
postinfecti
enceph
vzv
enceph
drug
choic
treatment
hsv
enceph
highdos
intraven
acyclovir
administ
earli
possibl
day
clinic
trial
current
assess
longer
cours
therapi
use
oral
valacyclovir
clinic
trial
regard
use
antivir
vzv
enceph
acyclovir
week
recommend
sever
infect
like
enceph
longer
cours
therapi
may
consid
immunocompromis
patient
foscarnet
prefer
agent
wherea
combin
therapi
foscarnet
ganciclovir
recommend
initi
treatment
cmv
enceph
tabl
antivir
proven
effect
enteroviru
enceph
drug
pleconaril
inhibitor
viral
replic
may
option
patient
sever
enteroviru
infect
use
oseltamivir
appropri
sever
influenza
also
specif
treatment
caus
enceph
although
experiment
therapi
may
consid
numer
virus
caus
viral
myocard
includ
coxsacki
virus
group
b
tabl
patient
recov
persist
cardiac
dysfunct
associ
oneyear
mortal
major
patient
acut
myocard
evid
heart
failur
sever
case
mechan
ventricular
assist
devic
support
necessari
resolut
cardiac
transplant
avail
although
immunosuppress
medicin
includ
corticosteroid
appli
mani
studi
viral
myocard
metaanalys
shown
effect
remain
controversi
sinc
reduc
mortal
systemat
review
use
intraven
immunoglobulin
ivig
viral
myocard
recommend
experiment
strategi
treatment
viral
myocard
develop
viral
hemorrhag
fever
vhf
caus
rna
virus
main
vector
involv
transmiss
rodent
arthropod
tabl
clinic
syndrom
hemorrhag
fever
secondari
capillari
leakag
due
increas
vascular
permeabl
clinic
manifest
depend
viru
involv
includ
hepat
enceph
andor
nephropathi
well
multiorgan
failur
dissemin
intravascular
coagulopathi
dic
one
common
characterist
find
mani
virus
wide
rang
casefat
rate
may
vari
immedi
isol
critic
effect
infect
control
prevent
transmiss
suspect
case
close
collabor
local
nation
public
health
author
necessari
alert
commun
possibl
outbreak
sinc
effect
therapeut
intervent
virus
care
larg
support
corticosteroid
use
antivir
drug
avail
treatment
hemorrhag
fever
virus
one
vaccin
wide
avail
ie
yellow
fever
vaccin
ribavirin
report
effect
therapi
lassa
fever
hemorrhag
fever
viru
infect
human
specif
immun
human
plasma
success
treat
certain
hemorrhag
fever
argentinian
hemorrhag
fever
emerg
therapi
activ
vhf
includ
ebola
describ
develop
primari
factor
respons
transmiss
viral
infect
icu
seem
inadequ
train
complianc
infect
control
procedur
use
nebul
open
suction
respiratori
secret
use
bipap
endotrach
intub
outdat
ventil
system
may
also
lead
spread
viral
infect
icu
set
infect
control
measur
includ
airborn
droplet
contact
precaut
disinfect
highli
activ
mani
virus
vaccin
possibl
prevent
infect
virus
influenza
b
virus
hbv
varicellazost
viru
yellow
fever
viru
polioviru
howev
vaccin
avail
major
viral
infect
herp
simplex
viru
hsv
antivir
therapi
need
control
viral
infect
prevent
vaccin
emerg
resist
virus
underlin
need
find
novel
antivir
novel
strategi
introduc
antivir
research
research
need
use
treatment
drugresist
viral
infect
despit
effect
antivir
therapi
certain
chronic
viral
infect
eg
hepat
b
viru
integr
genom
host
cell
becom
latent
therefor
new
therapi
complet
remov
viral
compon
integr
host
cell
need
patient
sever
viral
infect
often
hospit
intens
care
unit
icu
viral
infect
caus
sever
morbid
mortal
certain
host
tabl
mainstay
therapi
viral
infect
support
care
antivir
therapi
avail
limit
number
infect
includ
influenza
herpet
infect
novel
antivir
treatment
target
viral
protein
mostli
involv
enzymat
activ
viral
replic
machineri
host
protein
regul
immun
cellular
process
host
cell
involv
viral
life
cycl
need
valid
anim
human
random
control
studi
